Poortinga Sietske, Sondermann Wiebke, Förster Meike, Yazdi Amir S, Bieber Thomas, Balakirski Galina, Wilsmann-Theis Dagmar
Abteilung für Dermatologie, Bergman Clinics, Cromhoffsbleekweg 2, 7513, Enschede, Niederlande.
Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, Bonn, Deutschland.
Dermatologie (Heidelb). 2024 Feb;75(2):170-175. doi: 10.1007/s00105-023-05234-2. Epub 2023 Oct 11.
A number of new, highly effective biologic drugs for psoriasis have been approved over the past few decades, which raises the question whether psoriasis is still a disease that requires inpatient treatment.
We conducted a retrospective analysis of inpatient data between 2010 and 2019 (the last 10 years prior to the coronavirus disease 2019 [COVID-19] pandemic) from three German dermatology departments at university hospitals (Aachen, Bonn, and Essen). The data collected included age, gender, the primary admission diagnosis, length of stay (LOS), and number of all comorbidities recorded during hospitalization.
A total of 59,500 patients were admitted to the three dermatological departments in the defined 10-year period. Of these patients, psoriasis (L40.-) was the main diagnosis for 4322 (7.3%). An almost continuous increase was observed in all inpatient dermatological cases, which was as high as 27% in 2016 compared to 2010. For psoriasis patients, the most substantial increase in the number of admissions was reached in 2016 compared to 2010 and was as high as 45%. While there was a statistically significant reduction of the mean LOS for all dermatological inpatient cases from 6.4 ± 6.6 days in 2010 to 5.1 ± 4.6 days in 2019 (p < 0.001), the decrease in 2019 compared to 2010 (from 12.2 ± 5.5 to 8.9 ± 3.3 days) was significantly greater for the inpatient psoriasis patients compared to the inpatient population overall (p < 0.001).
Our data show a stable need for inpatient psoriasis facilities in Germany. Further analysis of hospital admissions after the end of the COVID-19 pandemic is needed to understand the ongoing influence of modern systemic treatment options on inpatient psoriasis care in Germany.
在过去几十年里，多种新型、高效的治疗银屑病的生物药物已获批准，这引发了一个问题，即银屑病是否仍是一种需要住院治疗的疾病。
我们对来自德国三所大学医院皮肤科（亚琛、波恩和埃森）2010年至2019年（2019冠状病毒病[COVID-19]大流行前的最后10年）的住院数据进行了回顾性分析。收集的数据包括年龄、性别、主要入院诊断、住院时间（LOS）以及住院期间记录的所有合并症数量。
在规定的10年期间，共有59500名患者入住这三个皮肤科。其中，银屑病（L40.-）是4322名患者（7.3%）的主要诊断。所有皮肤科住院病例几乎呈持续上升趋势，与2010年相比，2016年高达27%。对于银屑病患者，与2010年相比，2016年入院人数增长最为显著，高达45%。虽然所有皮肤科住院病例的平均住院时间从2010年的6.4±6.6天在统计学上显著减少至2019年的5.1±4.6天（p<0.001），但与总体住院患者相比，2019年银屑病住院患者的住院时间减少幅度（从12.2±5.5天降至8.9±3.3天）显著更大（p<0.001）。
我们的数据表明德国对银屑病住院设施仍有稳定需求。需要对COVID-19大流行结束后的医院入院情况进行进一步分析，以了解现代全身治疗方案对德国银屑病住院治疗的持续影响。
